Company profile
Biodesix, Inc.
NASDAQ: BDSX · Healthcare · Medical - Diagnostics & Research
#360 of 1,418 Healthcare companies by revenue69th-percentile growth
EA Score
57CFH 52DQ 57GM 71SS 58
v0.1 · 65/100 weight · provisional
↑ workforce scale, 3-yr revenue growth · ↓ listing tenure, balance-sheet leverage
Methodology →Revenue TTM
$96.1M
Rev growth YoY (TTM)
+29.1%
Net income (FY)
-$35.3M
Employees
334
as of 2026-08-14
Market cap
$193.7M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$88.5M$88.5M2025
Net income-$35.3M-$35.3M2025
Operating income-$27.9M-$27.9M2025
Total assets$87.5M$87.5M2025
Liabilities$89.9M$89.9M2025
Equity-$2.5M-$2.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Diagnostic Tests89%
Development Services11%
By geography
Not disclosed.
The read
What is Biodesix, Inc.’s revenue?
Biodesix, Inc. booked $88.5M in FY2025 revenue, growing 24% year over year — faster than most Healthcare companies we track, at a -39.8% net margin.
Peers · Healthcare
Pulmonx Corporation57CVaso Corporation68BCeriBell, Inc.49DCytokinetics, Incorporated59CFluent Corp.45DHarvard Bioscience, Inc.58CNeighbors
Boulder →Key facts
CEOScott Hutton
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersBoulder, CO
ExchangeNASDAQ: BDSX
Employees334
IPO date2020-10-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.